Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abbreviated, acute, adhesion, andin, answer, arm, asvascular, augment, ban, bank, Bay, bioavailability, bothin, bound, Bruno, calendar, CEEF, CEFF, cessation, cetuximab, choose, confirmatory, cornea, corneal, deliver, differentiated, disable, disabling, disgorgement, dissemination, durable, effort, eighteen, element, encouraging, entity, epidemiology, executory, exert, expansion, eyedrop, false, fashion, feasible, Fickling, formedwithin, formulary, fosbretabulin, front, glaucoma, greatest, havealready, Hill, inactivation, inclusion, infusion, Injectable, injected, Intracel, invention, ion, issuedEITF, journalBlood, kinase, Kingsbridge, leaflet, length, lethal, letter, leukemia, licence, lift, lost, lt, malignancy, middle, misleading, mobilizing, moiety, molecule, negotiated, negotiating, nonrefundable, occlusion, ofEITF, online, overwhelming, parallel, partner, Patricia, percent, pharmacoeconomic, pharmacy, pivotal, platinum, postmarket, PREA, preceing, prematurity, premium, primate, prolonged, proportion, rabbit, recovered, refractory, registry, regression, resale, responded, restitution, restoration, reversible, rodent, Roy, sarcoma, Schwieterman, secret, sickle, Simon, SPA, straight, strictly, sublicense, subpopulation, subset, supposed, television, thousand, tier, topreventthe, tyrosine, unable, unexpected, unsuccessful, unvalidated, vein, version, volume, Walicke, whichever, withintravenousZYBRESTAT, ZYBRESTAT, ZYBRESTATtm
Removed:
Acid, activated, administering, afforded, aim, angiogenic, anniversary, Antineoplastic, arose, blurring, cancel, cervical, charged, cisplatin, composition, compounded, concurrently, consolidated, corrected, counteracting, creator, defense, degenerative, description, destruction, Detroit, disciplined, Disodium, distortion, doxorubicin, elongation, Elucidation, enhancing, Ernst, essentially, Ester, evidenced, favor, Ford, functionally, generation, gleaned, hemorrhaging, hereditary, Histidine, immune, immunosuppression, importance, inactive, incurring, infiltrated, injunctive, investigating, involving, Isolation, Josephine, leak, LLP, loan, matter, measurable, mix, monetary, Mono, multimodality, open, organic, parent, participant, past, permitted, Pittsburgh, platform, portfolio, preferred, presence, proliferating, radiolabeled, relate, relief, repaid, repeat, scarring, scheduled, scope, secondary, secrecy, sixteen, structurally, synthesizing, thereof, traditional, transfer, Tromethamine, undergoing, underway, unfavorable, unpaid, unwanted, virtually, wAMD, wet, Young
Filing tables
Filing exhibits
Related press release
OTLC similar filings
Filing view
External links
Exhibit 32
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of OXiGENE, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report for the year ended December 31, 2007 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: March 14, 2008 | /s/ Richard Chin | |||
| Richard Chin, M.D. Chief Executive Officer | ||||
| Dated: March 14, 2008 | /s/ James B. Murphy | |||
| James B. Murphy, Chief Financial Officer | ||||
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.